MUMBAI, India, March 28 -- Intellectual Property India has published a patent application (202517006019 A) filed by Abbvie Operations Singapore Pte. Ltd., Singapore, on Jan. 24, for 'targeted protein degradation of parp14 for use in therapy.'
Inventor(s) include Perl, Nicholas Robert; and Kuntz, Kevin Wayne.
The application for the patent was published on March 28, under issue no. 13/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to compounds of formula I which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases."
The patent application was internationally filed on July 28, 2023, under International application No.PCT/US2023/028959....